Wedbush Adjusts Price Target on Biogen to $215 From $219
Biogen Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB) and Argenx Se (ARGX)
Biogen Analyst Ratings
RBC Capital Sticks to Its Buy Rating for Biogen (BIIB)
Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI), Biogen (BIIB) and SOPHiA GENETICS (SOPH)
Biogen's Strategic Diversification and Financial Strategy Garner Outperform Rating
Strategic Acquisitions and Clinical Catalysts Bolster Biogen's Buy Rating
Biogen (BIIB) Gets a Buy From Oppenheimer
Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Incyte (INCY)
Biogen Analyst Ratings
Wedbush Raises Biogen Price Target to $219 From $215, Maintains Neutral Rating
Biogen Analyst Ratings
Biogen's Strategic Acquisition of HI-Bio and Diversification Into Orphan Drug Market Prompt 'Buy' Rating
Biogen Analyst Ratings
Biogen (BIIB) Receives a Buy From Truist Financial
Argus Raises Biogen's Price Target to $250 From $240
Analysts Are Bullish on These Healthcare Stocks: Taysha Gene Therapies (TSHA), Biogen (BIIB)
Redburn Atlantic Adjusts Price Target on Biogen to $235 From $275, Keeps Neutral Rating
Biogen Analyst Ratings
No Data